We are live on ! Find out more
ALXN

Alexion Pharmaceuticals
ALXN

Delisted

ALXN was delisted on the 20th of July, 2021.

520 hedge funds and large institutions have $30.5B invested in Alexion Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 193 increasing their positions, 211 reducing their positions, and 72 closing their positions.

New
Increased
Maintained
Reduced
Closed

23% more call options, than puts

Call options by funds: $198M | Put options by funds: $161M

9% less repeat investments, than reductions

Existing positions increased: 193 | Existing positions reduced: 211

1.71% less ownership

Funds ownership: 99.28% → 97.57% (-1.7%)

5% less funds holding

Funds holding: 549 → 520 (-29)

33% less capital inflows, than outflows

Capital inflows: $1.25B | Capital outflows: $1.87B

33% less funds holding in top 10

Funds holding in top 10: 21 → 14 (-7)

49% less first-time investments, than exits

New positions opened: 37 | Existing positions closed: 72

Holders
520
Holders Change
-29
Holders Change %
-5.28%
% of All Funds
13.8%
Holding in Top 10
14
Holding in Top 10 Change
-7
Holding in Top 10 Change %
-33.33%
% of All Funds
0.37%
New
37
Increased
193
Reduced
211
Closed
72
Calls
$198​M
Puts
$161​M
Net Calls
+$36.5​M
Net Calls Change
+$45.8​M

ALXN Hedge Fund Activity: Q1 2016 in Review

520 of the 3,768 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q1 2016, worth a combined $30.5B — down 28% from $42.5B a quarter earlier.

Sellers outnumbered buyers: 72 funds closed out of ALXN and 37 opened new positions — a net loss of 35 holders — while 211 trimmed existing stakes and 193 added.

The largest buyer was Fidelity Investments, adding an estimated $274M. The largest seller was Wells Fargo, cutting an estimated $199M.

  • 520 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q1 2016, down from 549 in Q4 2015.
  • Funds reported $30.5B of Alexion Pharmaceuticals stock for Q1 2016, down 28% quarter-over-quarter.
  • 37 funds opened new Alexion Pharmaceuticals positions in Q1 2016 and 72 closed out, a net change of -35 holders.
  • The largest Alexion Pharmaceuticals buyer in Q1 2016 was Fidelity Investments, an estimated $274M added.
  • The largest Alexion Pharmaceuticals seller in Q1 2016 was Wells Fargo, an estimated $199M sold.

Based on aggregated 13F filings for Q1 2016.